title: Pharmacokinetics of tetra(m-hydroxyphenyl)chlorin in human plasma and individualized light dosimetry in photodynamic therapy.
abstract: The pharmacokinetics of the photosensitizer 5,10,15,20-tetra(m-hydroxyphenyl)chlorin (mTHPC) was investigated in the plasma of 20 patients by absorption and fluorescence spectroscopy. The temporal behavior was characterized by a rapid decrease in concentration during the first minutes after intravenous injection of 0.15 mg/kg mTHPC. A minimum concentration in the plasma was reached after about 45 min. The drug concentration then increased again, attaining a maximum after about 10 h, after which it decreased again with a halflife of about 30 h. Irradiation tests in the oral cavity at different time intervals after the injection revealed that the tissue reaction was only partially correlated with the mTHPC plasma level. The tissue response was stronger at later drug-light intervals (1-4 days) than during the first hours after injection even though the mTHPC plasma concentration was higher at the shorter times. Relative mTHPC concentrations were also measured in the mucosae of the oral cavity, the esophagus and the bronchi of 27 patients by light-induced fluorescence spectroscopy using an optical fiber-based spectrometer. These measurements were performed prior to photodynamic therapy (PDT), 4 days after injection of the photosensitizer. Highly significant linear correlations were found between the relative mTHPC concentrations in the mucosae of these three organs. Likewise, the plasma levels of mTHPC measured just before PDT were significantly correlated with the mTHPC concentrations in the three types of mucosae mentioned above. These results indicate that mTHPC plasma levels measured just before PDT can be used for PDT light dosimetry.
authors.affiliation: Institute of Environmental Engineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland. Thomas.Glanzmann@epfl.ch
authors.forename: T
authors.initials: T
authors.lastname: Glanzmann
authors.forename: C
authors.initials: C
authors.lastname: Hadjur
authors.forename: M
authors.initials: M
authors.lastname: Zellweger
authors.forename: P
authors.initials: P
authors.lastname: Grosiean
authors.forename: M
authors.initials: M
authors.lastname: Forrer
authors.forename: J P
authors.initials: JP
authors.lastname: Ballini
authors.forename: P
authors.initials: P
authors.lastname: Monnier
authors.forename: H
authors.initials: H
authors.lastname: van den Bergh
authors.forename: C K
authors.initials: CK
authors.lastname: Lim
authors.forename: G
authors.initials: G
authors.lastname: Wagnières
mesh_terms: D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008297:Male; D008652:Mesoporphyrins / Q000097:blood / Q000493:pharmacokinetics*; D010778:Photochemotherapy; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics*; D013050:Spectrometry, Fluorescence
chemical_list: D008652:Mesoporphyrins; D011838:Radiation-Sensitizing Agents; C072269:temoporfin